Evidence map›Paper›PMID 33447026›Full record

ArticleInternational journal of chronic obstructive pulmonary disease

Assessing the Usefulness of the Prevexair Smartphone Application in the Follow-Up High-Risk Patients with COPD.

Juan Luis Rodríguez Hermosa, Antonia Fuster Gomila, Luis Puente Maestu, Carlos Antonio Amado Diago, Francisco Javier Callejas González, Rosa Malo De Molina Ruiz, Manuel E Fuentes Ferrer, Jose Luis Alvarez-Sala, Myriam Calle Rubio

Abstract read
In one paragraph

Article in International journal of chronic obstructive pulmonary disease. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Juan Luis Rodríguez HermosaPulmonology Department, Hospital Clínico San Carlos, Madrid, Spain.ORCID 0000-0003-0552-2484
Antonia Fuster GomilaPulmonology Department, Hospital U. Son Llátzer, Palma De Mallorca, Balearic Islands, Spain.
Luis Puente MaestuPulmonology Department, Hospital U. Gregorio Marañón, Madrid, Spain.ORCID 0000-0001-8501-0117
Carlos Antonio Amado DiagoPulmonology Department, Hospital U. Marqués de Valdecilla, Santander, Cantabria, Spain.ORCID 0000-0002-5598-1753
Francisco Javier Callejas GonzálezPulmonology Department, Complejo Hospitalario U. de Albacete, Albacete, Spain.
Rosa Malo De Molina RuizPulmonology Department, Hospital U. Puerta de Hierro de Majadahonda, Madrid, Spain.
Manuel E Fuentes FerrerDepartment of Medicine Preventive, San Carlos Health Research Institute (IdISSC), Madrid, Spain.
Jose Luis Alvarez-SalaPulmonology Department, Hospital Clínico San Carlos, Madrid, Spain.ORCID 0000-0002-5091-0286
Myriam Calle RubioPulmonology Department, Hospital Clínico San Carlos, Madrid, Spain.ORCID 0000-0002-3890-2742

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis manuscript analyzes the exacerbations recorded by the Prevexair application through the daily analysis of symptoms in high-risk patients with COPD and explores its usefulness in assessing clinical stability with respect to that reported in visits. PATIENTS AND

methodsThis study is a multi-centre cohort of COPD patients with the exacerbator phenotype who were monitored over 6 months. The Prevexair application was installed on the patients' smartphones. Patients used the app to record symptom changes, use of medication and use of healthcare resources. It is not established a recommended action plan when worsening of symptoms. At their clinical visit during the follow-up period, patients were asked about exacerbations suffered during these 6 months of monitoring. The investigators who conducted the visit were blinded about the Prevexair app records.

resultsThe patients experienced a total of 185 exacerbations according to daily records in the app whereas only 64 exacerbations were recalled during medical visits. Perception became more accurate for severe exacerbations (kappa 0.6577), although we found no factors that predicted poor recall. The proportion of 72.5% patients were classified as unstable if the exacerbations captured by Prevexair were used to define stability, versus 47.8% if the exacerbations recall in visit was used. Two-thirds of the exacerbations recorded in the Prevexair application were not reported to doctors during their clinical visits. Almost half were treated with oral corticosteroids and/or antibiotics and more than one-quarter of the exacerbations treated did not seek medical attention.

conclusionThe findings of this cohort study confirm that patients do not always remember the exacerbations suffered during their medical visit. The prevexair application is useful in monitoring COPD patients at high risk, in order to a better assessment of exacerbations of COPD during medical visits. Further research must be carried out to evaluate this strategy in clinical practice.

Indexed as

Pulmonary Disease, Chronic ObstructiveAdrenal Cortex HormonesCohort StudiesDisease ProgressionFollow-Up StudiesHumansSmartphoneAdrenal Cortex Hormoneschronic obstructive pulmonary diseaseclinical predictionelectronic patient recordexacerbationsmanagementmobile healthtelemonitoring

Identifiers

PMID33447026
PMCPMC7802911

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.